Yoav Golan, M.D., M.S.Date:
Tuesday, May 10, 2011Time:
12:30 p.m. to 1:30 p.m. Central European TimeLocation:
Poster Area Hall 5Poster Topic 99:
Clostridium difficilePoster ID#:
P19682011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, MarylandMay 11-14, 2011Poster Presentation Information: Title:
Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile InfectionPresenter:
Thomas J. Louie, M.D.Date:
Thursday, May 12, 2011 Time:
4:30 p.m. to 6:00 p.m. Eastern TimeSession:
Presidential Poster Session BLocation:
Exhibit HallPoster ID#:
B126About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved